Toi et al. BMC Cancer 2010, 10:56 http://www.biomedcentral.com/1471-2407/10/56 Table 1 Clinical characteristics of the cohort Characteristic Geographic origin Type of cohot Centralized HER2 assessment Centralized clinical data collection Length of follow-up (months) Total Number of patients Parameter HER2 status by IHC HER2 status by FISH HER2 test at the local hospital 2+ 3+ Centrally reviewed IHC 0 1+ 2+ 3+ HER2 score on repeat testing Mean (s.d.) Min - Max Hormone receptor status ER+ PR+ ER+ PR- ER- PR+ ER- PR- ER unknown, PR- ER unknown, PR unknown Nodal status Negative 1 to 3 positive nodes 4 to 10 positive nodes > 10 positive nodes Status missing Tumor size < = 2 cm >2 cm & < = 5 cm >5 cm Missing Prior adjuvant therapy Adj HT Adj CT Adj HT only Adj CT only Adj HT & Adj CT neither HT nor CT Number of pre-chemotherapy before trastuzumab treatment* 0 Summary data Total 20 (26.7) 55 (73.3) 11 (14.7) 14 (18.7) 18 (24.0) 32 (42.7) 148 (101) 0 - 290 10 (13.3) 2 (2.7) 3 (4.0) 60 (80.0) 0 0 21 (28.0) 23 (30.7) 8 (10.7) 17 (22.0) 6 (8.0) 9 (12.0) 37 (49.3) 17 (22.7) 12 (16.0) 30 (40.0) 51 (68.0) 5 (6.7) 26 (34.7) 25 (33.3) 19 (25.3) 41 (54.7) Page 3 of 10 Cohort Japan Clinic-based no no 3.4-63.3 75 Number of patients (%) 75 (100) 9(12.0) Log10 HER2 expression Median Log10 HER2 expression Median 11 (28.9) 27 (71.1) 1 (2.6) 2 (5.3) 9 (23.7) 26 (68.4) 210 (71) 0 - 290 6 (15.8) 1 (2.6) 0 31 (81.6) 0 0 14 (36.8) 9 (23.7) 4 (10.5) 7 (18.4) 4 (10.5) 5 (13.2) 19 (50.0) 6 (15.8) 8 (21.1) 15 (39.5) 23 (60.5) 2 (5.3) 10 (26.3) 13 (34.2) 13 (34.2) 18 (47.4) 9 (24.3) 28 (75.7) 10 (27.0) 12 (32.4) 9 (24.3) 6 (16.2) 84 (87) 0 - 290 4 (10.8) 1 (2.7) 3 (8.1) 29 (78.4) 0 0 7 (18.9) 14 (37.8) 4 (10.8) 10 (27.0) 2 (5.4) 4 (10.8) 18 (48.7) 11 (29.7) 4 (10.8) 15 (40.5) 28 (75.7) 3 (8.1) 16 (43.2) 12 (32.4) 6 (16.2) 23 (62.2)